Closed System Transfer Devices Market Size is expected to grow significantly from 2022 to 2028, due to the rapid introduction of CSTDs into clinical practice to safeguard healthcare practitioners from exposure to hazardous drugs. In addition, the escalating use of cytotoxic drugs in healthcare settings for the treatment of cancers and other diseases will further proliferate the demand for closed system drug transfer devices over the coming years. CSTD refers to a drug transfer device that can mechanically prohibit the entry of environmental contaminants in the system as well as prevent the escape of vapor concentrations or hazardous drugs outside the system. These closed systems, equipped with the mechanism to regulate differential pressure outside and inside the vial, limit the aerosol generation and consequently reduce exposure of workers.
Rising prevalence of gastrointestinal stromal tumors (GIST) and the commendable increase in oncology drug approvals will foster closed system transfer devices market trends through 2028. As per data from the American Society of Clinical Oncology, nearly 4,000-6,000 adults in the U.S. are diagnosed with GIST each year. These factors could augment the need for closed system transfer devices for use in compounding and administering chemotherapy drugs. Furthermore, the recent introduction of lean management principles in healthcare to train pharmacists involved in compounding procedures will also amplify the market expansion in the coming years.
Based on closing mechanism, the closed system transfer devices market from the Luer-lock systems segment will depict a strong growth rate through 2028. Growth from this segment is a result of the high level of spills and aerosols caused by this type of needleless connector, thus stimulating the need for CSTDs to ensure leak-free transfer of drugs. Considering end-use, the oncology centers and clinics segment will amass considerable gains over the estimated timeline, owing to the mounting incidence of cancer and the potential surge in the adoption of chemo closed system devices.
The North America closed system transfer devices market is set to register appreciable revenue by 2028. This is on account of the escalating consumer out-of-pocket spending on healthcare, alongside the rising burden of breast cancer in the U.S. According to the American Cancer Society’s estimates, nearly 281,550 new invasive breast cancer cases are likely to be diagnosed among women in the country in 2021. These aforementioned factors will push the demand for closed system transfer devices for chemotherapy administration in the coming years.
Key players operating in the market are Codan Medizinische Geräte GmbH & Co KG, Caragen Ltd., Victus, Yukon Medical, Corvida Medical, Equashield, JMS North America Corporation, B. Braun Medical, ICU Medical, Becton, Dickinson and Company (BD), and Baxter International. These firms are implementing strategies such as new product launches, acquisitions, and mergers to strengthen their presence in the competitive market. For instance, in December 2021, B. Braun Medical Inc. announced the availability of its OnGuard 2 CSTD in the U.S., designed to make healthcare practitioners meet USP <800> quality standards for safe handling of hazardous drugs.
Disrupted healthcare systems due to the novel coronavirus pandemic have hindered the management and diagnosis of non-COVID disease conditions, including cancer. While this factor may have asserted a negative influence on the industry over the past months, the escalating rate of new drug approvals during the crisis may aid its recovery. For example, over the course of 2020, the U.S. FDA approved around 57 novel medicines, which could boost the deployment of CSTDs for enhanced protection against hazardous drugs during compounding and administration processes.
Market, By Closing Mechanism
Market, By Type
Market, By Component
Market, By Technology
Market, By End-use
The above information is provided for the following regions and countries: